NS Partners Ltd Sells 6,046 Shares of Boston Scientific Co. (NYSE:BSX)

NS Partners Ltd lowered its position in shares of Boston Scientific Co. (NYSE:BSX - Free Report) by 1.6% during the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission. The fund owned 362,485 shares of the medical equipment provider's stock after selling 6,046 shares during the quarter. Boston Scientific comprises 1.3% of NS Partners Ltd's investment portfolio, making the stock its 24th biggest holding. NS Partners Ltd's holdings in Boston Scientific were worth $32,377,000 at the end of the most recent quarter.

Other institutional investors have also bought and sold shares of the company. TFC Financial Management Inc. boosted its position in shares of Boston Scientific by 308.8% during the 4th quarter. TFC Financial Management Inc. now owns 278 shares of the medical equipment provider's stock worth $25,000 after purchasing an additional 210 shares in the last quarter. Global Wealth Strategies & Associates boosted its position in shares of Boston Scientific by 423.7% during the 4th quarter. Global Wealth Strategies & Associates now owns 309 shares of the medical equipment provider's stock worth $28,000 after purchasing an additional 250 shares in the last quarter. West Oak Capital LLC bought a new position in shares of Boston Scientific during the 4th quarter worth about $29,000. Dunhill Financial LLC boosted its position in shares of Boston Scientific by 86.4% during the 3rd quarter. Dunhill Financial LLC now owns 328 shares of the medical equipment provider's stock worth $28,000 after purchasing an additional 152 shares in the last quarter. Finally, Capital Performance Advisors LLP bought a new position in shares of Boston Scientific during the 3rd quarter worth about $30,000. Institutional investors own 89.07% of the company's stock.

Remove Ads

Insider Activity at Boston Scientific

In other Boston Scientific news, EVP Arthur C. Butcher sold 17,313 shares of the firm's stock in a transaction on Monday, February 3rd. The shares were sold at an average price of $101.80, for a total value of $1,762,463.40. Following the completion of the transaction, the executive vice president now directly owns 5,502 shares of the company's stock, valued at $560,103.60. This trade represents a 75.88 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, EVP John Bradley Sorenson sold 6,528 shares of the firm's stock in a transaction on Friday, February 7th. The shares were sold at an average price of $104.97, for a total transaction of $685,244.16. Following the completion of the transaction, the executive vice president now directly owns 26,449 shares of the company's stock, valued at approximately $2,776,351.53. The trade was a 19.80 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last ninety days, insiders sold 137,302 shares of company stock worth $14,319,269. Corporate insiders own 0.50% of the company's stock.

Boston Scientific Stock Performance

Shares of BSX stock traded up $0.90 during trading hours on Wednesday, hitting $96.42. 8,790,877 shares of the company were exchanged, compared to its average volume of 5,775,970. Boston Scientific Co. has a 52-week low of $65.52 and a 52-week high of $107.17. The stock has a market capitalization of $142.29 billion, a price-to-earnings ratio of 77.14, a P/E/G ratio of 2.79 and a beta of 0.77. The company has a current ratio of 1.08, a quick ratio of 1.02 and a debt-to-equity ratio of 0.41. The firm has a fifty day simple moving average of $100.66 and a 200 day simple moving average of $91.49.

Boston Scientific (NYSE:BSX - Get Free Report) last released its quarterly earnings data on Wednesday, February 5th. The medical equipment provider reported $0.70 earnings per share for the quarter, beating analysts' consensus estimates of $0.65 by $0.05. Boston Scientific had a net margin of 11.07% and a return on equity of 17.80%. Research analysts predict that Boston Scientific Co. will post 2.85 earnings per share for the current fiscal year.

Wall Street Analysts Forecast Growth

BSX has been the topic of a number of research analyst reports. Deutsche Bank Aktiengesellschaft raised shares of Boston Scientific from a "hold" rating to a "buy" rating and set a $108.00 price objective on the stock in a research report on Friday, January 10th. UBS Group raised their price target on shares of Boston Scientific from $105.00 to $130.00 and gave the company a "buy" rating in a research report on Friday, February 7th. Truist Financial raised their price target on shares of Boston Scientific from $100.00 to $110.00 and gave the company a "buy" rating in a research report on Wednesday, December 18th. Needham & Company LLC reaffirmed a "hold" rating on shares of Boston Scientific in a research report on Monday, March 3rd. Finally, Royal Bank of Canada raised their price target on shares of Boston Scientific from $105.00 to $116.00 and gave the company an "outperform" rating in a research report on Thursday, February 6th. Two equities research analysts have rated the stock with a hold rating, twenty-one have issued a buy rating and one has issued a strong buy rating to the company's stock. According to data from MarketBeat.com, Boston Scientific currently has a consensus rating of "Moderate Buy" and an average target price of $108.91.

Boston Scientific Company Profile

Boston Scientific Corporation develops, manufactures, and markets medical devices for use in various interventional medical specialties worldwide. It operates through two segments, MedSurg and Cardiovascular. The company offers devices to diagnose and treat gastrointestinal and pulmonary conditions, such as resolution clips, biliary stent systems, stents and electrocautery enhanced delivery systems, direct visualization systems, digital catheters, and single-use duodenoscopes; devices to treat urological conditions, including ureteral stents, catheters, baskets, guidewires, sheaths, balloons, single-use digital flexible ureteroscopes, holmium laser systems, artificial urinary sphincter, laser system, fiber, and hydrogel systems; and devices to treat neurological movement disorders and manage chronic pain, such as spinal cord stimulator system, proprietary programming software, radiofrequency generator, indirect decompression systems, practice optimization tools, and deep brain stimulation system.